Loading...
•
Jun 30, 2022
Edgewise Therapeutics Q2 2022 Earnings Report
Reported financial results for the second quarter of 2022 and provided recent business highlights.
Key Takeaways
Edgewise Therapeutics reported positive results from their EDG-5506 clinical trials in individuals with Becker muscular dystrophy, initiated Phase 2 trials in BMD, and anticipates starting Phase 2 trials in DMD in 2022. The company's cash, cash equivalents, and marketable securities totaled $248.4 million as of June 30, 2022.
Announced positive 2-month interim results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy (BMD).
Initiated Phase 2 trial in BMD and expect to start Phase 2 trial in Duchenne muscular dystrophy (DMD) in 2022.
Cash, cash equivalents and marketable securities were $248.4 million as of June 30, 2022.
Net loss per share was $0.32.
Forward Guidance
Edgewise anticipates that its cash resources on hand will be sufficient to support its planned growth and operations through the end of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...